MA31385B1 - Utilisation d'inhibiteurs de hdac pour le traitement de la destruction osseuse - Google Patents

Utilisation d'inhibiteurs de hdac pour le traitement de la destruction osseuse

Info

Publication number
MA31385B1
MA31385B1 MA32356A MA32356A MA31385B1 MA 31385 B1 MA31385 B1 MA 31385B1 MA 32356 A MA32356 A MA 32356A MA 32356 A MA32356 A MA 32356A MA 31385 B1 MA31385 B1 MA 31385B1
Authority
MA
Morocco
Prior art keywords
treatment
hdac inhibitors
bone destruction
bone
destruction
Prior art date
Application number
MA32356A
Other languages
Arabic (ar)
English (en)
Inventor
Peter Wisdom Atadja
Joseph Daniel Growney
Wenlin Shao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39643800&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31385(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31385B1 publication Critical patent/MA31385B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

La présente invention concerne une utilisation d'inhibiteurs de hdac pour le traitement de la destruction osseuse causée par le cancer, des maladies inflammatoires et l'ostéoporose.
MA32356A 2007-05-30 2009-11-20 Utilisation d'inhibiteurs de hdac pour le traitement de la destruction osseuse MA31385B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94073507P 2007-05-30 2007-05-30
PCT/US2008/064944 WO2008150782A1 (fr) 2007-05-30 2008-05-28 Utilisation d'inhibiteurs de hdac pour le traitement de la destruction osseuse

Publications (1)

Publication Number Publication Date
MA31385B1 true MA31385B1 (fr) 2010-05-03

Family

ID=39643800

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32356A MA31385B1 (fr) 2007-05-30 2009-11-20 Utilisation d'inhibiteurs de hdac pour le traitement de la destruction osseuse

Country Status (20)

Country Link
US (2) US20100179208A1 (fr)
EP (1) EP2162129B1 (fr)
JP (1) JP2010529028A (fr)
KR (1) KR101516446B1 (fr)
CN (1) CN101715344A (fr)
AU (1) AU2008260236A1 (fr)
BR (1) BRPI0812788A2 (fr)
CA (1) CA2687274A1 (fr)
CL (1) CL2008001553A1 (fr)
DK (1) DK2162129T3 (fr)
ES (1) ES2726401T3 (fr)
IL (1) IL201466A0 (fr)
LT (1) LT2162129T (fr)
MA (1) MA31385B1 (fr)
MX (1) MX2009012624A (fr)
RU (1) RU2009148601A (fr)
SI (1) SI2162129T1 (fr)
TN (1) TN2009000448A1 (fr)
TW (1) TW200904412A (fr)
WO (1) WO2008150782A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY150437A (en) * 2008-03-26 2014-01-30 Novartis Ag Hydroxamate-based inhibitors of deacetylases b
US20110053925A1 (en) * 2009-08-28 2011-03-03 Novartis Ag Hydroxamate-Based Inhibitors of Deacetylases
CN115778950B (zh) * 2022-11-23 2024-01-26 山西医科大学第二医院 组蛋白去乙酰化酶抑制剂tmp195在制备促进成骨形成药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
BRPI0614090A2 (pt) * 2005-08-03 2011-03-09 Novartis Ag uso de inibidores da hdac para o tratamento do mieloma

Also Published As

Publication number Publication date
US20100179208A1 (en) 2010-07-15
MX2009012624A (es) 2009-12-07
ES2726401T3 (es) 2019-10-04
US20120029047A1 (en) 2012-02-02
IL201466A0 (en) 2010-05-31
RU2009148601A (ru) 2011-07-10
BRPI0812788A2 (pt) 2014-12-02
EP2162129B1 (fr) 2019-03-06
EP2162129A1 (fr) 2010-03-17
KR20100017434A (ko) 2010-02-16
KR101516446B1 (ko) 2015-04-30
CA2687274A1 (fr) 2008-12-11
AU2008260236A1 (en) 2008-12-11
DK2162129T3 (da) 2019-06-11
JP2010529028A (ja) 2010-08-26
WO2008150782A1 (fr) 2008-12-11
CN101715344A (zh) 2010-05-26
TW200904412A (en) 2009-02-01
TN2009000448A1 (en) 2011-03-31
LT2162129T (lt) 2019-06-25
SI2162129T1 (sl) 2019-08-30
CL2008001553A1 (es) 2009-06-05

Similar Documents

Publication Publication Date Title
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
CY1118523T1 (el) Πεπτιδικες ενωσεις για την θεραπεια του ανθεκτικου status epilepticus
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
EA201070247A1 (ru) Ингибиторы протеасом
MA31918B1 (fr) Agents et épitopes de liaison à wise
NO20073788L (no) Kjemiske forbindelser
EA200801362A1 (ru) Пиримидинил бензотиофеновые соединения
MX2012004258A (es) Inhibidores de la tirosina quinasa de bruton.
TW200626068A (en) Active compounds for seed treatment
PT1206474E (pt) Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2
NO20081636L (no) FAP - inhibitorer
DK1853602T3 (da) Kemiske forbindelser
MA35638B1 (fr) 2-thiopyrimidinones
EA200602221A1 (ru) Новое применение пептидных соединений для лечения боли при тригеминальной невралгии
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
MX2020004099A (es) Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
ATE530540T1 (de) Pyrimidonverbindungen als gsk-3-inhibitoren
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
EA200602129A1 (ru) Новое применение пептидных соединений для лечения дискинезии
EA201270049A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
FR2907011B1 (fr) Utilisation de la citrulline pour le traitement des etats de denutrition
MA31435B1 (fr) Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2
CY1114023T1 (el) Διυποκατεστημενης φθαλαζινης ανταγωνιστες σηματοδοτικης οδου hedgehog
DK1831209T3 (da) Inhibitorer af CDC25-phosphatase